Literature DB >> 3165301

Variable Philadelphia breakpoints and potential lineage restriction of bcr rearrangement in acute lymphoblastic leukemia.

L M Secker-Walker1, H M Cooke, P J Browett, C A Shippey, J D Norton, E Coustan-Smith, A V Hoffbrand.   

Abstract

Philadelphia (Ph1) chromosome breakpoints in acute lymphoblastic leukemia (ALL) are of two kinds: those within the breakpoint cluster region (bcr+), as in chronic myeloid leukemia (CML), and those outside it (bcr-). These encode different c-abl messenger RNAs (mRNAs), p210 and p190, respectively. It has been suggested that one class of Ph+ ALL (bcr+) may be a variant of CML arising in a multipotent stem cell, the other (bcr-) de novo ALL initiated in a lymphoid-committed progenitor. Thirty-two cases of ALL (12 Ph1+, ten chromosomally normal, and ten non-mitotic cases) were investigated for bcr involvement. Breakpoints were found within five Ph1+ and in one normal case. There was no difference in clinical features, common ALL antigen (CALLA) positivity, cytogenetics, or response to treatment between the 6 bcr+ and 7 Ph1+ bcr- patients. Myeloid antigen expression was found in 2 bcr+ cases. Bcr rearrangement appeared to be restricted to the lymphoblastic component of marrow or blood in at least four bcr+ cases. In one case, separated myeloid and lymphoid cell fractions were both bcr+. Potential heterogeneity of the Ph1+ target cell, as seen in this study, may be more important in determining disease outcome than the precise location of the Ph breakpoint.

Entities:  

Mesh:

Year:  1988        PMID: 3165301

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Localization of preferential sites of rearrangement within the BCR gene in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  C T Denny; N P Shah; S Ogden; C Willman; T McConnell; W Crist; A Carroll; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

2.  Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene.

Authors:  M Kelliher; A Knott; J McLaughlin; O N Witte; N Rosenberg
Journal:  Mol Cell Biol       Date:  1991-09       Impact factor: 4.272

3.  Unexpected heterogeneity of BCR-ABL fusion mRNA detected by polymerase chain reaction in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  A L Hooberman; J J Carrino; D Leibowitz; J D Rowley; M M Le Beau; Z A Arlin; C A Westbrook
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

4.  Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells.

Authors:  J McLaughlin; E Chianese; O N Witte
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

5.  The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.

Authors:  S Li; R L Ilaria; R P Million; G Q Daley; R A Van Etten
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307

6.  Philadelphia chromosome-positive chronic myelogenous leukemia with deleted fusion of BCR and ABL genes.

Authors:  K Ohyashiki; J H Ohyashiki; H Iwabuchi; T Tauchi; A Iwabuchi; K Toyama
Journal:  Jpn J Cancer Res       Date:  1990-01

7.  Systematic interactome mapping of acute lymphoblastic leukemia cancer gene products reveals EXT-1 tumor suppressor as a Notch1 and FBWX7 common interactor.

Authors:  Sarah Daakour; Leon Juvenal Hajingabo; Despoina Kerselidou; Aurelie Devresse; Richard Kettmann; Nicolas Simonis; Franck Dequiedt; Jean-Claude Twizere
Journal:  BMC Cancer       Date:  2016-05-26       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.